Hematology/Oncology

Top Story

FDA clears IND application for natural killer cell therapy for glioblastoma multiforme

January 22, 2020

The FDA cleared an investigational new drug application for CYNK-001, a natural killer cell therapy, for the treatment of glioblastoma multiforme.

CYNK-001 (Celularity) is an investigational, cryopreserved, allogeneic NK cell therapy derived from placental hematopoietic stem cells for IV or intratumoral administration.

Meeting NewsPerspective

Sociodemographic factors may influence survival among young adults with colorectal cancer

January 22, 2020

Young adults with colorectal cancer who resided in areas with the lowest incomes and high school graduation rates had a 24% increased risk for death than their…

Meeting News

Atezolizumab-bevacizumab combination delays quality-of-life deterioration in hepatocellular carcinoma

January 22, 2020

Atezolizumab in combination with bevacizumab delayed time to deterioration of quality of life, physical functioning and role functioning compared with standard-of-care…

Tislelizumab extends PFS in squamous non-small cell lung cancer

January 22, 2020

A randomized phase 3 trial designed to evaluate the addition of tislelizumab to first-line chemotherapy for patients with squamous non-small cell lung cancer met its…

Feature

Recommendations seek ‘similarity across trials’ of therapies for sickle cell disease

January 22, 2020

Sickle cell disease, the most common inherited red blood cell disorder in the United States, is associated with debilitating physical symptoms, including …

More Headlines »

CME